Skip to content

Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

A Randomized Controlled Trial of Cryotherapy for Prevention and Reduction of Severity of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01789658
Enrollment
53
Registered
2013-02-12
Start date
2012-10-31
Completion date
2016-10-31
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Nutrition Aspect of Cancer, Oral Mucositis, Pain

Keywords

Oral Mucositis, Children, Cryotherapy, Hematopoietic Stem Cell Transplantation

Brief summary

Oral mucositis (OM) is a common adverse effect of chemotherapy, radiotherapy and conditioning regimens before Hematopoietic Stem Cell Transplantation (HSCT). The aim of this study is to effectiveness of cryotherapy as a prophylactic treatment in children undergoing HSCT.

Detailed description

There is a complex pathobiology behind OM; chemo and radiotherapy affects the mucosa and submucosa causing DNA-strand brakes and generation of reactive oxygen species (ROS). This initiates a cascade of events, among others activation of transcription factors, up-regulation of pro-inflammatory cytokines, and activation of macrophages and proteases leading to tissue injury causing symptoms such as erythema, edema, ulceration, taste perception alterations, and mouth dryness. OM often causes local and systemic infections, fatigue, pain, and difficulties in basal functions such as swallowing (and hence drinking and eating) and talking and reduces patients' psychological well-being. Nearly 90 % of pediatric patients undergoing HSCT are afflicted with OM. In pediatric patients mucositis is reported as one of the most painful and debilitating side effects during cancer treatment.Beyond a significant suffering for the patient it is hence associated with higher costs for health care and increased mortality. The current scientific situation regarding prevention and treatment of OM has been summarized in Cochrane reports showing limited data on adults and practically missing data on children and adolescents. Concluding guidelines from these reports emphasize the need for well conducted randomized controlled trials (RCT's) to evaluate and refine treatments in order to establish evidence based interventions. The use of cryotherapy to prevent oral mucositis in patients who are receiving high-dose chemotherapy as a conditioning agent prior to HSCT continue to show evidence in the adult population. The aim of this study is to compare treatment with cryotherapy (Arm 1)with a standard oral care protocal (Arm 2) ARM 1 Children are instructed to use chew on ice-chips, ingest ice-cream or ice-water during infusion of chemotherapy as part of the conditioning treatment prior to HSCT. Melted ice should be replaced by new as soon as possible. Children receiving a 24-hour infusion are instructed to use cryotherapy for one hour 4 times a day. ARM 2 Standard care for prevention and management of oral mucositis Primary outcome * Degree and duration of Oral mucositis Secondary outcomes * Oral pain * Opioid use * Duration of parenteral nutrition * Weight loss * Duration of neutropenic fever * Duration of antibiotic treatment * Duration of hospitalization * Emotional and psychological status * C reactive protein (CRP) and s-albumin correlation to grade of Oral Mucositis

Interventions

OTHERCryotherapy

Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.

Sponsors

The Swedish Childhood Cancer Foundation
CollaboratorUNKNOWN
Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

Age between 4-18 Undergoing Hematopoietic Stem Cell Transplantation in Sweden sufficient knowledge in swedish to understand the protocols -

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Mucositis grade - WHO Oral Toxicity ScaleDaily until engraftment, an expected average of 20 days.WHO-Oral toxicity scale Grade 0 - No mucositis Grade 1 - Erythema and/or soreness Grade 2 - Erythema and/or ulcers. Can eat solid food. Grade 3 - Erythema and/or Ulcers. No solid food but can ingest liquids. Grade 4 - Oral alimentation not possible.

Secondary

MeasureTime frameDescription
Emotional and Psychological statusDaily until engraftment, an expected average of 20 days.Beck youth inventories for depression and anxiety
Mouth PainDaily until Engraftment an expected average of 20 daysMouth Pain measured with Numerical Rating scale(NRS)for children \>7 years and parents and Facial Pain Scale(FPS) for children \< 7 years
Mucositis grade - Children´s International Mucositis Evaluation Scale (ChiMES)Daily until engraftment, an expected average of 20 days.Daily evaluation by child and parent.
Pain - Childrens Hospital Eastern Ontario Pain Scale (CHEOPS)Daily until Engraftment an expected average of 20 days.Daily assessment by nurse

Other

MeasureTime frameDescription
Duration of HospitalisationDuring hospitalization in connection with HSCT, an expected average of 25 daysCounted from day 0 until discharge either home or to region hospital.
Opioid consumptionDuring hospitalization in connection with HSCT, an expected average of 25 daysDays with, and dose of morphine-equivalent opioids
S-AlbuminDuring hospitalization in connection with HSCT, an expected average of 25 daysIn correlation to grade of Oral Mucositis
C reactive proteinDuring hospitalization in connection with HSCT, an expected average of 25 daysLevel of p-CRP in comparison to grade of mucositis
Duration of parenteral nutritionDuring hospitalization in connection with HSCT, an expected average of 25 daysDays with Total Parenteral Nutrition
Weight LossDuring hospitalization in connection with HSCT, an expected average of 25 daysWeight Loss in kilograms from admission to date of engraftment
Duration of Antibiotic treatmentDuring hospitalization in connection with HSCT, an expected average of 25 daysDays with antibiotics
Duration of febrile neutropeniaUntil engraftment, an expected average of 20 daysDays with fever \>38.0 degrees

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026